{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T21:06:14Z","timestamp":1779570374391,"version":"3.53.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bulcan.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:39:23Z","timestamp":1751413163000},"page":"S83-S98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["S\u00e9lection de produits transfusionnels pour limiter l\u2019immunisation HLA avant allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques avec donneur mismatch (SFGM-TC)"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8473-202X","authenticated-orcid":false,"given":"Roberto","family":"Crocchiolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Avias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Baud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Croisille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Harfouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Pajot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.bulcan.2025.03.016_bib0385","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"12S","key":"10.1016\/j.bulcan.2025.03.016_bib0390","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.bulcan.2021.01.024","volume":"108","author":"Dubois","year":"2021","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2025.03.016_bib0395","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"Ciurea","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2025.03.016_bib0400","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2019.02.020","article-title":"Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes","volume":"25","author":"Bramanti","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0405","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-015-0182-9","article-title":"Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets","volume":"8","author":"Chang","year":"2015","journal-title":"J Hematol Oncol J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.03.016_bib0410","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation","volume":"88","author":"Ciurea","year":"2009","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0415","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bmt.2011.131","article-title":"Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT","volume":"47","author":"Yoshihara","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2025.03.016_bib0420","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2025.03.016_bib0425","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/bmt.2017.10","article-title":"Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation","volume":"52","author":"Yamashita","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0430","doi-asserted-by":"crossref","first-page":"4025073","DOI":"10.1155\/2016\/4025073","article-title":"Donor specific anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantation","volume":"2016","author":"Kongtim","year":"2016","journal-title":"Adv Hematol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0435","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.transproceed.2015.11.027","article-title":"Progress in desensitization of the highly HLA sensitized patient","volume":"48","author":"Jordan","year":"2016","journal-title":"Transplant Proc"},{"issue":"1S","key":"10.1016\/j.bulcan.2025.03.016_bib0440","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.bulcan.2019.07.011","article-title":"Haploidentical hematopoietic stem cell transplant: how to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"107","author":"Dubois","year":"2020","journal-title":"Bull Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2025.03.016_bib0445","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jtct.2024.09.005","article-title":"ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies","volume":"30","author":"Kongtim","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11S","key":"10.1016\/j.bulcan.2025.03.016_bib0450","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2025.03.016_bib0455","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/voxs.12073","article-title":"Managing the platelet refractory patient","volume":"9","author":"Murphy","year":"2014","journal-title":"ISBT Sci Ser"},{"issue":"Suppl. 5","key":"10.1016\/j.bulcan.2025.03.016_bib0460","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/tme.12409","article-title":"HLA Matchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets","volume":"27","author":"O\u2019Rafferty","year":"2017","journal-title":"Transfus Med"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0465","series-title":"Transfusion de plaquettes\u00a0: produits, indications","year":"2015"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0470","first-page":"1","article-title":"Prevalence, risk factors, and outcomes of platelet transfusion refractoriness in critically ill patients: a retrospective cohort study","volume":"2021","author":"Arabi","year":"2021","journal-title":"Crit Care Res Pract"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0475","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.13597","article-title":"Platelet refractoriness\u00a0\u2013\u00a0practical approaches and ongoing dilemmas in patient management","volume":"171","author":"Stanworth","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0480","doi-asserted-by":"crossref","first-page":"125367","DOI":"10.3389\/fimmu.2023.1125367","article-title":"Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: from mechanisms and determinants to therapeutic prospects","volume":"14","author":"Couvidou","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0485","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-0039.2012.01852.x","article-title":"HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management","volume":"79","author":"Pavenski","year":"2012","journal-title":"Tissue Antigens"},{"issue":"5","key":"10.1016\/j.bulcan.2025.03.016_bib0490","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1399-0039.1985.tb02225.x","article-title":"Natural HLA antibodies","volume":"26","author":"Tongio","year":"1985","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0495","first-page":"199","article-title":"Epitopes of HLA antibodies found in sera of normal healthy males and cord blood","author":"El-Awar","year":"2008","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.bulcan.2025.03.016_bib0500","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.transproceed.2011.12.049","article-title":"Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients","volume":"44","author":"Hyun","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0505","doi-asserted-by":"crossref","first-page":"101680","DOI":"10.1016\/j.trim.2022.101680","article-title":"Effects of different sensitization events on HLA alloimmunization in renal transplant cases; a retrospective observation in 1066 cases","volume":"75","author":"Pandey","year":"2022","journal-title":"Transpl Immunol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.03.016_bib0510","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1537-2995.2009.02556.x","article-title":"Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors","volume":"50","author":"Kakaiya","year":"2010","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.bulcan.2025.03.016_bib0515","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1111\/trf.12727","article-title":"Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy","volume":"54","author":"De Clippel","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0520","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.transproceed.2017.02.004","article-title":"Association between HLA antibodies and different sensitization events in renal transplant candidates","volume":"49","author":"Akgul","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0525","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.trim.2016.03.002","article-title":"Comprehensive assessment of sensitizing events and anti-HLA antibody development in women awaiting kidney transplantation","volume":"36","author":"Picascia","year":"2016","journal-title":"Transpl Immunol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0530","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007890-200208270-00018","article-title":"Flow cytometric evaluation of pregnancy-induced anti-HLA immunization and blood transfusion-induced reactivation","volume":"74","author":"Rebibou","year":"2002","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.bulcan.2025.03.016_bib0535","doi-asserted-by":"crossref","first-page":"939.e1","DOI":"10.1016\/j.jtct.2021.07.017","article-title":"Transfusions in aplastic anemia patients cause HLA alloimmunization: comparisons of current and past cohorts demonstrate progress","volume":"27","author":"Julen","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0540","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/tan.14704","article-title":"Prevalence and risk factors of antibodies to HLA according to different cut-off values of mean fluorescence intensity in haploidentical allograft candidates: a prospective study of 3805 subjects","volume":"100","author":"Ma","year":"2022","journal-title":"HLA"},{"issue":"10","key":"10.1016\/j.bulcan.2025.03.016_bib0545","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2003-08-2724","article-title":"Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients","volume":"105","author":"Slichter","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2025.03.016_bib0550","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00007890-198205000-00013","article-title":"Immunogenicity of serum HLA antigens in allogeneic combinations","volume":"33","author":"Pellegrino","year":"1982","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0555","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V68.3.627.627","article-title":"Quantitative analysis of platelet surface HLA by W6\/32 anti-HLA monoclonal antibody","volume":"68","author":"Kao","year":"1986","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2025.03.016_bib0560","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00007890-199202010-00034","article-title":"HLA in human serum\u00a0\u2013\u00a0quantitation of class I by enzyme immunoassay","volume":"53","author":"McDonald","year":"1992","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bulcan.2025.03.016_bib0565","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2141.1990.tb02624.x","article-title":"HLA class I expression on erythrocytes and platelets from patients with systemic lupus erythematosus, rheumatoid arthritis and from normal subjects","volume":"75","author":"Botto","year":"1990","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.03.016_bib0570","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1537-2995.1990.30290162897.x","article-title":"A study of HLA (Bg) on red cells and platelets by immunoblotting with monoclonal antibodies","volume":"30","author":"Giles","year":"1990","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0575","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1537-2995.1986.26486262749.x","article-title":"HLA antigens on red cells. Implications for achieving low HLA antigen content in blood transfusions","volume":"26","author":"Rivera","year":"1986","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.bulcan.2025.03.016_bib0580","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jtct.2021.05.003","article-title":"Pretransplantation red blood cell and platelet transfusion burden in de novo myelodysplastic syndrome undergoing allogeneic transplantation","volume":"27","author":"Konuma","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.bulcan.2025.03.016_bib0585","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1537-2995.2006.00793.x","article-title":"Prevalence of HLA antibodies in transfused patients with and without red cell antibodies","volume":"46","author":"Buetens","year":"2006","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.bulcan.2025.03.016_bib0590","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/trf.15306","article-title":"Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens","volume":"59","author":"Belizaire","year":"2019","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0595","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/TP.0b013e3182419864","article-title":"Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion","volume":"93","author":"Balasubramaniam","year":"2012","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.bulcan.2025.03.016_bib0600","first-page":"1361","article-title":"Increased antibody responsiveness to blood transfusions in pediatric patients","volume":"58","author":"Scornik","year":"1994","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bulcan.2025.03.016_bib0605","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2017-07-799270","article-title":"Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization","volume":"131","author":"Saris","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0610","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fmed.2018.00084","article-title":"Blood and blood components: from similarities to differences","volume":"5","author":"Garraud","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.bulcan.2025.03.016_bib0620","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2003-03-0940","article-title":"Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness","volume":"103","author":"Seftel","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0625","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2141.1990.tb04356.x","article-title":"Transfusion of ABO-mismatched platelets leads to early platelet refractoriness","volume":"75","author":"Carr","year":"1990","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.03.016_bib0630","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1600-0609.1993.tb00150.x","article-title":"The role of ABO matching in platelet transfusion","volume":"50","author":"Heal","year":"1993","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.03.016_bib0635","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1046\/j.1537-2995.2001.41080984.x","article-title":"Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions","volume":"41","author":"Pappalardo","year":"2001","journal-title":"Transfusion"},{"issue":"25","key":"10.1016\/j.bulcan.2025.03.016_bib0615","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMc2034764","article-title":"Reducing the need for HLA-matched platelet transfusion","volume":"384","author":"Cardillo","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0640","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood.V72.3.964.bloodjournal723964","article-title":"Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration","volume":"72","author":"Andreu","year":"1988","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2025.03.016_bib0645","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.V77.1.201.201","article-title":"Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial","volume":"77","author":"van Marwijk Kooy","year":"1991","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2025.03.016_bib0650","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood.V85.7.1736.bloodjournal8571736","article-title":"Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study","volume":"85","author":"Novotny","year":"1995","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bulcan.2025.03.016_bib0655","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0660","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/trf.12317","article-title":"Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response","volume":"54","author":"Jackman","year":"2014","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0665","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0887-7963(98)80002-3","article-title":"Meta analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA alloimmunization and refractoriness to random-donor platelet transfusions","volume":"12","author":"Vamvakas","year":"1998","journal-title":"Transfus Med Rev"},{"issue":"2","key":"10.1016\/j.bulcan.2025.03.016_bib0670","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.tmrv.2010.11.002","article-title":"Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products","volume":"25","author":"Slichter","year":"2011","journal-title":"Transfus Med Rev"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0675","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V74.3.1172.1172","article-title":"Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets","volume":"74","author":"Schiffer","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0680","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3389\/fimmu.2018.01251","article-title":"Storage-induced platelet apoptosis is a potential risk factor for alloimmunization upon platelet transfusion","volume":"9","author":"Saris","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0685","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1399-0039.1982.tb01438.x","article-title":"HLA-B7 on human red blood cells. Improved detection by radioactive anti-IgG test","volume":"19","author":"Salama","year":"1982","journal-title":"Tissue Antigens"},{"issue":"1S","key":"10.1016\/j.bulcan.2025.03.016_bib0690","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.bulcan.2018.08.016","article-title":"[Transfusion in autologous and allogenic hematopoietic stem cell transplant: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]","volume":"106","author":"Giraud","year":"2019","journal-title":"Bull Cancer"},{"issue":"2S","key":"10.1016\/j.bulcan.2025.03.016_bib0695","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.bulcan.2023.03.004","article-title":"[Transfusion management and immuno-hematological follow-up after allogeneic hematopoietic cell transplantation: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]","volume":"111","author":"Xhaard","year":"2024","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0700","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000446043","article-title":"Cross sectional guidelines for therapy with blood components and plasma derivatives: chapter 5 Human Albumin Revised","volume":"43","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0705","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bulcan.2025.03.016_bib0710","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Escourt","year":"2017","journal-title":"Br J Hematol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.03.016_bib0715","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1111\/j.1537-2995.2011.03194.x","article-title":"Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients","volume":"51","author":"Fontaine","year":"2011","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.bulcan.2025.03.016_bib0720","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/trf.12175","article-title":"Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review","volume":"53","author":"Pavenski","year":"2013","journal-title":"Transfusion (Paris)"},{"issue":"10","key":"10.1016\/j.bulcan.2025.03.016_bib0725","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.5858\/arpa.2021-0051-OA","article-title":"Use of human leukocyte antigen (HLA)-incompatible platelet units in HLA platelet-refractory patients with limited number of or low-level HLA donor-specific antibodies results in permissive transfusions","volume":"146","author":"Sullivan","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0730","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/trf.15108","article-title":"HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience","volume":"59","author":"Karlstr\u00f6m","year":"2019","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0735","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.5001\/omj.2022.81","article-title":"Evaluation of human leucocyte antigen mediated platelet transfusion refractoriness and platelet crossmatching assay in patients with hematologic disorders","volume":"37","author":"Neanaey","year":"2022","journal-title":"Oman Med J"},{"issue":"4","key":"10.1016\/j.bulcan.2025.03.016_bib0740","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/trf.12395","article-title":"Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review","volume":"54","author":"Vassallo","year":"2014","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.bulcan.2025.03.016_bib0745","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/ndt\/gfp233","article-title":"Pre-kidney-transplant blood transfusions do not improve transplantation outcome: a Dutch national study","volume":"24","author":"Aalten","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2025.03.016_bib0750","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/TP.0b013e318271d776","article-title":"Effects of HLA-matched blood transfusion for patients awaiting renal transplantation","volume":"94","author":"Magee","year":"2012","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0755","doi-asserted-by":"crossref","first-page":"e15438","DOI":"10.1111\/tan.15438","article-title":"Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: protecting HLA-A and HLA-B antigens through eplet analysis","volume":"103","author":"Durand","year":"2024","journal-title":"HLA"},{"issue":"3","key":"10.1016\/j.bulcan.2025.03.016_bib0380","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.2020007199","article-title":"An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial","volume":"137","author":"Marsh","year":"2021","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T20:24:13Z","timestamp":1779567853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125002620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0007455125002620"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.03.016","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00e9lection de produits transfusionnels pour limiter l\u2019immunisation HLA avant allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques avec donneur mismatch (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}